Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab + Atezolizumab or Polatuzumab Vedotin in R/R B-Cell Non-Hodgkin's Lymphoma
NCT03533283Phase 2Completed
- Sponsor
- Roche
- Start
- May 2018
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of glofitamab in non-Hodgkin lymphoma (NHL), sponsored by Roche. Started May 2018; status: completed.
02
Drugs
glofitamab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03533283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03533283.